Which of the following is true regarding estrogens and progestins in replacement therapy?

The statement that estrogens and progestins are often found together in combination products is accurate because combination hormone replacement therapy (HRT) is designed to provide both hormones for women who have not undergone a hysterectomy. Estrogen alone can increase the risk of endometrial cancer in women with an intact uterus, so progestins are added to mitigate that risk by protecting the endometrium. This combination helps to alleviate menopausal symptoms while also addressing safety concerns regarding the potential effects of estrogen on the uterus.

Combination products are widely used because they can simplify treatment regimens and enhance the effectiveness of therapy in managing symptoms such as hot flashes, mood swings, and vaginal dryness. This combination approach also allows providers to tailor treatments according to the individual needs of patients, making it a common practice in hormone replacement therapy.